IntelliChem Provides Global ELN Solution to AstraZeneca
IntelliChem, Inc., a leading provider of intelligent electronic lab notebooks (iELN) for discovery and development, today announced that AstraZeneca has deployed IntelliChem Synthesis within the Process Chemistry division of its Global Process Research & Development (GPR&D) Group.
Dr. David Haywood, Vice President of the Global Process Research & Development Group at AstraZeneca, explains, “As one of the leaders in the global pharmaceutical industry, AstraZeneca is focused on turning good ideas into effective medicines that make a real difference in important areas of healthcare. To improve our competitive position, GPR&D realized that the valuable scientific data and intellectual property trapped within Process Chemists’ laboratory notebooks needed to be captured and shared globally.”
After an extensive search, AstraZeneca GPR&D selected IntelliChem Synthesis, an intelligent ELN solution tailored to the needs of Process Chemists, to solve the knowledge management challenges of the Process Chemistry division. Using IntelliChem Synthesis, scientists are able to quickly set up experiments electronically, record experimental results, and capture analytical data.
The creation of a searchable global database of laboratory information gives AstraZeneca’s GPR&D scientists the ability to quickly search for and replicate past experiments, increasing the reuse of existing information and saving valuable time. By utilizing the intelligent tools included within the IntelliChem software, users can automatically scale experiments based on various constraints and perform detailed campaign and cost planning.
AstraZeneca decided to use IntelliChem to deploy a completely electronic ELN solution, rather than opting for a hybrid deployment like many other companies in the industry. This design gives AstraZeneca all the benefits of eliminating paper lab notebooks without the extra burden of managing a hybrid system.
IntelliChem counts five of the top ten global pharmaceutical companies as customers, but AstraZeneca is the first to deploy a completely electronic ELN solution. The resulting benefits range from productivity improvements to cost savings through the elimination of paper lab notebook administration.
“IntelliChem is excited to be chosen as AstraZeneca’s global partner for intelligent ELN within GPR&D,” described Dr. Paul van Eikeren, President and CEO, IntelliChem. “By deploying a completely electronic system, they have raised the bar for the industry in terms of ELN adoption. As IntelliChem strives to set the industry standard for intelligent ELN, our ability to work with leading companies like AstraZeneca is vital to our success.”
David Haywood added, “I am confident the IntelliChem team understands our business and will give us all the required support and guidance to help us achieve great success with our intelligent ELN deployment.”
About Intelligent Electronic Laboratory Notebooks
Intelligent electronic lab notebooks (iELN) not only allow companies to replace paper laboratory notebooks with an electronic, searchable system, but they also provide collaborative decision-support tools to help scientists and engineers make better decisions. Only intelligent ELN systems can deliver the benefits that pharmaceutical and biotechnology companies require to dramatically improve productivity and efficiency in their global research and development organizations.
About IntelliChem
IntelliChem, Inc. is the leading provider of intelligent electronic lab notebooks (iELN) for discovery and development. Pharmaceutical, biotechnology, and fine chemicals companies can improve productivity, enable collaboration, improve quality, and ensure regulatory compliance through the adoption of IntelliChem solutions. IntelliChem Discovery & Development Solutions (IDS) were developed and validated through partnership with six major pharmaceutical companies, including Merck & Co., Pfizer, and Bristol-Myers Squibb. IntelliChem is a privately held company with headquarters and development facilities located in Bend, Oregon. For more information, visit www.intellichem.com .
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. Worldwide, AstraZeneca has six major research and development sites, four discovery facilities and a clinical research site, in total, employing more than 11,500 R&D staff members in Canada, France, India, Japan, Sweden, United Kingdom and the United States.
